Patents Assigned to KalVista Pharmaceuticals Limited
  • Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride
    Patent number: 9512065
    Abstract: The invention provides new polymorphs of N—[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: December 6, 2016
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Julian Scott Northen, John Mykytiuk
  • INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20160168123
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: August 14, 2014
    Publication date: June 16, 2016
    Applicant: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy EDWARDS, David Michael EVANS, Premji MEGHANI, Andrew Richard NOVAK
  • Benzylamine derivatives as inhibitors of plasma kallikrein
    Patent number: 9234000
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: January 12, 2016
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20150342910
    Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
    Type: Application
    Filed: January 9, 2014
    Publication date: December 3, 2015
    Applicant: KalVista Pharmaceuticals Limited
    Inventors: Gary Paul COOK, Garry Thomas GWOZDZ, Theodore Patrick LASLO
  • Benzylamine derivatives as inhibitors of plasma kallikrein
    Patent number: 9051249
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 9, 2015
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker
  • BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20140213611
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 31, 2014
    Applicant: KalVista Pharmaceuticals Limited
    Inventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker